Skip to Content
Merck
All Photos(2)

Documents

SAB4200202

Sigma-Aldrich

Anti- INI1/SNF5 antibody, Mouse monoclonal

clone 2C2, purified from hybridoma cell culture

Synonym(s):

Anti-BAF47, Anti-RDT, Anti-RTPS1, Anti-SMARCB1, Anti-SNF5L1, Anti-SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1, Anti-Sfh1p, Anti-Snr1, Anti-hSNFS

Sign Into View Organizational & Contract Pricing


About This Item

MDL number:
UNSPSC Code:
12352203
NACRES:
NA.41

biological source

mouse

conjugate

unconjugated

antibody form

purified from hybridoma cell culture

antibody product type

primary antibodies

clone

2C2, monoclonal

form

buffered aqueous solution

mol wt

antigen ~44 kDa

species reactivity

monkey, bovine, canine, mouse, rat, human

concentration

~1.0 mg/mL

technique(s)

immunocytochemistry: suitable
western blot: 1.0-2.0 μg/mL using HeLa cell extracts

isotype

IgG2a

UniProt accession no.

shipped in

dry ice

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

human ... SMARCB1(6598)

General description

INI1/SNF5, also known as SWItch/sucrose non-fermentable (SWI/SNF) related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1, is encoded by the gene mapped to human chromosome 22q11.2. This gene codes for an essential component of chromatin-remodelling SWI/SNF multiprotein complexes.
Monoclonal Anti-INI1/SNF5 (mouse IgG2a isotype) is derived from the hybridoma 2C2 produced by the fusion of mouse myeloma cells (SP2) and splenocytes from mouse immunized with a human INI1 fusion protein. Integrase interactor 1 (INI1)/sucrose non-fermentable 5 (SNF5) binds to human immunodeficiency virus type 1 (HIV-1) integrase.

Immunogen

human INI1 fusion protein.

Application

Monoclonal Anti-INI1/SNF5 antibody produced in mouse has been used in immunoblotting and immunocytochemistry.

Biochem/physiol Actions

INI1/sucrose non-fermentable 5 (SNF5) plays a vital role in transcriptional activation of inducible genes through chromatin remodelling. Loss of function mutations of the gene is associated with the pathogenesis of aggressive pediatric cancer and epithelioid schwannoma. The encoded protein triggers DNA-joining activity of the HIV-1 integrase in vitro. Additionally, it might also help in targeting the viral DNA to active genes. SNF5 interacts with E1 protein of human papillomavirus (HPV) and thus, enhances the efficiency of HPV DNA replication.
Integrase interactor 1 (INI1)/sucrose non-fermentable 5 (SNF5) is recruited to HIV-1 preintegration complexes before nuclear migration and represses the basal human immunodeficiency virus type 1 promoter activity. This gene is a tumor suppressor and mutations in it have been associated with various tumors.

Physical form

Solution in 0.01M phosphate buffered saline pH 7.4, containing 15 mM sodium azide.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Epigenetics and cancer: altered chromatin remodeling via Snf5 loss leads to aberrant cell cycle regulation
Sansam CG and Roberts CWM
Cell Cycle, 5(6), 621-624 (2006)
Daniel D Shapiro et al.
Clinical and translational medicine, 13(5), e1267-e1267 (2023-05-25)
Renal medullary carcinoma (RMC) is a highly aggressive cancer in need of new therapeutic strategies. The neddylation pathway can protect cells from DNA damage induced by the platinum-based chemotherapy used in RMC. We investigated if neddylation inhibition with pevonedistat will
Pavlos Msaouel et al.
Cancer cell, 37(5), 720-734 (2020-05-04)
Renal medullary carcinoma (RMC) is a highly lethal malignancy that mainly afflicts young individuals of African descent and is resistant to all targeted agents used to treat other renal cell carcinomas. Comprehensive genomic and transcriptomic profiling of untreated primary RMC
SMARCB1/INI1 Loss in Epithelioid Schwannoma: A Clinicopathologic and Immunohistochemical Study of 65 Cases.
Jo VY and Fletcher CDM
American Journal of Surgical Pathology, 41, 1013-1022 (2017)
Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer
Versteege I
Nature, 394, 203-206 (1998)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service